+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Biogen Inc. - logo

Founded in 1978 Biogen Inc is a global biotechnology company with its headquarters in Cambridge, Massachusetts. In 2003 Biogen merged with Idec Pharmaceuticals to create Biogen Idec and acquired Syntonix Pharmaceuticals in 2007. In 2015 the company returned to its original name Biogen Inc and acquired Convergence Pharmaceuticals. Biogen focuses on drug discovery for a range of conditions including neuropathic pain, hemophilia, organ failure, neuromuscular disorders and oncology. Their product portfolio includes Rituxan, Avonex, Tecfidera and Eloctate.

Collaboration Deals in Pharmaceuticals 2019-2024 - Product Thumbnail Image

Collaboration Deals in Pharmaceuticals 2019-2024

  • Report
  • September 2024
  • 1150 Pages
  • Global
From
Licensing Deals in Pharmaceuticals 2019-2024 - Product Thumbnail Image

Licensing Deals in Pharmaceuticals 2019-2024

  • Report
  • September 2024
  • 1400 Pages
  • Global
From
Targeted Oncology Therapeutics: Lung Cancers - Product Thumbnail Image

Targeted Oncology Therapeutics: Lung Cancers

  • Report
  • October 2021
  • 82 Pages
  • Global
From
Biosimilars Market 2024-2028 - Product Thumbnail Image

Biosimilars Market 2024-2028

  • Report
  • August 2024
  • 180 Pages
  • Global
From
Kidney Cancer Drugs Global Market Report 2024 - Product Thumbnail Image

Kidney Cancer Drugs Global Market Report 2024

  • Report
  • February 2024
  • 175 Pages
  • Global
From
US Biosimilar industry outlook to 2028 - Product Thumbnail Image

US Biosimilar industry outlook to 2028

  • Report
  • October 2023
  • 85 Pages
  • United States
From
From
From
From
From
From
From
Non-hodgkin Lymphoma (NHL) Therapeutics Market 2024-2028 - Product Thumbnail Image

Non-hodgkin Lymphoma (NHL) Therapeutics Market 2024-2028

  • Report
  • July 2024
  • 190 Pages
  • Global
From
From
From
From
Loading Indicator